FORT LAUDERDALE, Fla., May 29, 2026
Sunshine Biopharma announced that the United States Patent and Trademark Office has issued U.S. Patent No. 12,624,066 B2, titled “Compounds and Methods for Treatment of Coronavirus Infection.” The newly granted patent protects the company’s proprietary technology designed to inhibit coronavirus replication through a novel class of small-molecule compounds. The patent marks a significant milestone in Sunshine Biopharma’s ongoing efforts to develop innovative therapies capable of addressing current and future coronavirus threats.
Patent Covers Novel PLpro-Targeting Antiviral Compounds
The patented technology includes a series of small-molecule inhibitors discovered and developed by Sunshine Biopharma scientists during the COVID-19 pandemic. These compounds target the papain-like protease (PLpro) enzyme, a critical component of the coronavirus lifecycle that helps the virus replicate while suppressing the body’s natural immune response. By inhibiting this enzyme, the compounds are designed to interfere with viral replication and potentially reduce the severity of infection. According to the company, targeting PLpro offers a promising strategy because the enzyme plays an essential role across multiple coronavirus strains.
Technology Designed to Address Future Variants
Coronaviruses are known for their ability to mutate rapidly, leading to the emergence of new variants with altered transmissibility, disease severity, or resistance to existing therapies. Sunshine Biopharma stated that its patented approach focuses on a highly conserved viral function, increasing the likelihood that the treatment could remain effective even as the virus evolves. The company believes this strategy may help address future coronavirus outbreaks and strengthen global preparedness against emerging viral threats. Company leadership emphasized that continued innovation remains critical, as experts continue to warn that new coronavirus mutations could potentially trigger future public health challenges.
Advertisement
Advancing Toward Clinical Development
The compounds protected under the newly issued patent have reached a stage where they are ready for Good Laboratory Practice (GLP) studies, an important preclinical step required before entering human clinical trials. Sunshine Biopharma plans to continue investing in research and development to advance these antiviral candidates through the regulatory pathway. Beyond its coronavirus program, the company maintains a growing portfolio of pharmaceutical products and proprietary drug-development initiatives, including K1.1 mRNA, an mRNA-lipid nanoparticle therapy being developed for liver cancer. With the issuance of this patent, Sunshine Biopharma strengthens its intellectual property portfolio while positioning itself to advance novel therapies targeting infectious diseases and other serious medical conditions.
Source: Sunshine Biopharma press release
